A recent study by the Hector Institute for Translational Brain Research (HITBR) at the Central Institute of Mental Health (CIMH) in Mannheim provides the first detailed cellular insights into how ...
The UK-based psychedelics medicine company Beckley Psytech announced Thursday that it has dosed its first patients in a Phase IIa study (NCT05434156) of ELE-101, a patent-protected synthetic ...
Psilocybin—the psychoactive compound in "magic mushrooms"—is gaining scientific attention for its potential in treating neuropsychiatric conditions including depression, anxiety, substance use ...
Entropy Neurodynamics has secured an Australian patent covering proprietary crystalline forms of psilocin, strengthening its ...
A not-so-trippy ‘magic mushroom’-derived compound may offer a way of treating certain neuropsychiatric conditions, without hallucinatory side effects. Scientists from the University of Padova (Italy) ...
Entropy Neurodynamics has released positive topline safety and efficacy results from Cohort 1 of a Phase II trial of its lead ...
The Pentagon has changed its drug screening policy to test service members for psilocin, indicating the use of psilocybin mushrooms, according to an Aug. 18 memo. Psilocin will be added to drug ...
VANCOUVER, British Columbia--(BUSINESS WIRE)-- Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to ...
See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. Mushroom gummies sold to promote brain health have been found to ...
VANCOUVER, British Columbia & STUART, Fla.--(BUSINESS WIRE)--Lobe Sciences, Ltd. ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma, Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results